You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Todos said that after implementing its automation equipment, Majl will be able to run approximately 1,500 PCR-based COVID-19 tests per day.
The test uses a technology called Switch-Blocker that is co-owned by the companies and enables both viral detection and strain discrimination.
The collaboration builds on an oligonucleotide supply agreement the partners signed in 2019 for Clear Labs' nanopore sequencing-based food safety testing.
Osang is seeking US Food and Drug Administration Emergency Use Authorization for its PCR-based SARS-CoV-2 diagnostic kit and plans to distribute it to US airports.
The firm said that the National Institute for Health and Care Excellence has selected its EarlyCDT Lung test for its Diagnostics Assessment Guidance.
Centogene will install Fujirebio's Lumipulse G1200 instruments in its laboratories to analyze samples it collects from travelers using its oropharyngeal swabs.
Applied DNA Sciences previously partnered with Stony Brook University Hospital to validate the test, which received Emergency Use Authorization in May.
Todos also announced a $23.8 million sales agreement this week with an unnamed Wisconsin laboratory covering testing equipment and supplies.
Quotient's CE-marked MosaiQ COVID-19 Antibody Microarray is designed to detect human immunoglobulin G and M antibodies against SARS-CoV-2.
Novacyt has initially committed to supply 288,000 tests per week to the DHSC, and it has an option to expand the agreement.